Universal Rapid Human Immunodeficiency Virus Screening at Delivery: A Cost-Effectiveness Analysis

Table 5

Univariate sensitivity analysis of universal rapid HIV screening relative to standard of care I.

Variable	Detected range	Estimated incremental cost ($)	Estimated incremental QALY	Incremental cost-effectiveness ratio ($/QALY)
QALY per prevention of 1 case of MTCT	5~25	39,827.83	1.32~6.60	30,185.10~6,037.02
Estimated lifetime medical cost of PAH	$250k~$550k	57,811.19~(−21,356.02)	5.01	11,530.13~(−4,259.34)
HIV prevalence	0.5%~10%	40,396.22~36,539.30	5.09~4.60	7,943.45~7,943.45
HIV annual cumulative incidence	0.01%~0.15%	113,233.84~(−20,316.76)	0.58~8.65	196,399.01~(−2,348.85)
Cost of rapid test	$11.90~$16.32	15,661.65~50,341.69	5.01	3,123.63~10,040.38
Cost of neonatal prophylaxis	$185~$210	39,827.83~40,063.20	5.01	7,943.45~7,990.39